Supernus Pharma (SUPN) Reports Q4 Revenue of $155M

Supernus Pharma (NASDAQ: SUPN) reported Q4 revenue of $155 million versus the consensus estimate of $149.42 million.

GUIDANCE:

Supernus Pharma sees FY2022 revenue of $640-680 million, versus the consensus of $707.32 million.

For earnings history and earnings-related data on Supernus Pharma (SUPN) click here.

You May Also Be Interested In

• Paychex (PAYX) Tops Q1 EPS by 2c
• On Holding AG (ONON) Stock: Market Doesn't Appreciate Brand's Potential, Says Analyst
• KB Home (KBH) PT Lowered to $50 at RBC Capital